Impact of the C-terminal domain of topoisomerase IIα on the DNA cleavage activity of the human enzyme

Biochemistry

Volumn 44, Issue 34, 2005, Pages 11546-11554

  Dickey, Jennifer S ^a   Osheroff, Neil ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CATALYST ACTIVITY; CELLS; DNA; DRUG THERAPY; HYDROPHILICITY; MUTAGENESIS; PHOSPHORESCENCE; TUMORS;

ENZYMATIC FUNCTION; ENZYMATIC FUNCTIONS; LOCALIZATION; PHOSPHORYLATION;

ENZYME KINETICS;

AMINO ACID; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; ETOPOSIDE; MUTANT PROTEIN; SINGLE STRANDED DNA; TOPOISOMERASE IIALPHA; TYROSINE; UNCLASSIFIED DRUG; VIRUS ENZYME;

ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHLORELLA VIRUS; CONTROLLED STUDY; DNA CLEAVAGE; DNA STRAND BREAKAGE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; HYDROPHILICITY; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; PARAMECIUM; PARAMECIUM BURSARIA CHLORELLA VIRUS 1; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, NEOPLASM; BINDING SITES; CRITHIDIA FASCICULATA; DNA; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ETOPOSIDE; HUMANS; KINETICS; PEPTIDE FRAGMENTS; PLASMIDS;

CHLORELLA VIRUS; EUKARYOTA; PARAMECIUM BURSARIA CHLORELLA VIRUS 1;

EID: 23944501757     PISSN: 00062960     EISSN: None     Source Type: Journal    
DOI: 10.1021/bi050811l     Document Type: Article

References (55)

1. Wang, J. C. (1996) DNA topoisomerases, Annu. Rev. Biochem. 65, 635-692.
2. Wang, J. C. (1998) Moving one DNA double helix through another by a type II DNA topoisomerase: the story of a simple molecular machine, Q. Rev. Biophys. 31, 107-144.
3. Burden, D. A., and Osheroff, N. (1998) Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme, Biochim. Biophys. Acta 1400, 139-154.
4. Nitiss, J. L. (1998) Investigating the biological functions of DNA topoisomerases in eukaryotic cells, Biochim. Biophys. Acta 1400, 63-81.
5. Fortune, J. M., and Osheroff, N. (2000) Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice, Prog. Nucleic Acid Res. Mol. Biol. 64, 221-253.
6. Champoux, J. J. (2001) DNA topoisomerases: Structure, Function, and Mechanism, Annu. Rev. Biochem. 70, 369-413.
7. Wilstermann, A. M., and Osheroff, N. (2003) Stabilization of eukaryotic topoisomerase II-DNA cleavage complexes, Curr. Top. Med. Chem. 3, 321-338.
8. Drake, F. H., Zimmerman, J. P., McCabe, F. L., Bartus, H. F., Per, S. R., Sullivan, D. M., Ross, W. E., Mattern, M. R., Johnson, R. K., and Crooke, S. T. (1987) Purification of topoisomerase II from amsacrine-resistant P388 leukemia cells. Evidence for two forms of the enzyme, J. Biol. Chem. 262, 16739-16747.
9. Drake, F. H., Hofmann, G. A., Bartus, H. F., Mattern, M. R., Crooke, S. T., and Mirabelli, C. K. (1989) Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II, Biochemistry 28, 8154-8160.
10. Hsiang, Y. H., Wu, H. Y., and Liu, L. F. (1988) Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells, Cancer Res. 48, 3230-3235.
11. Isaacs, R. J., Davies, S. L., Sandri, M. I., Redwood, C., Wells, N. J., and Hickson, I. D. (1998) Physiological regulation of eukaryotic topoisomerase II, Biochim. Biophys. Acta 1400, 121-137.
12. Austin, C. A., and Marsh, K. L. (1998) Eukaryotic DNA topoisomerase IIβ, BioEssays 20, 215-226.
13. Woessner, R. D., Mattern, M. R., Mirabelli, C. K., Johnson, R. K., and Drake, F. H. (1991) Proliferation- and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ. 2, 209-214.
14. Yang, X., Li, W., Prescott, E. D., Burden, S. J., and Wang, J. C. (2000) DNA topoisomerase IIb and neural development, Science 287, 131-134.
15. Berger, J. M., Gamblin, S. J., Harrison, S. C., and Wang, J. C. (1996) Structure and mechanism of DNA topoisomerase II, Nature 379, 225-232.
16. Baguley, B. C., and Ferguson, L. R. (1998) Mutagenic properties of topoisomerase-targeted drugs, Biochim. Biophys. Acta 1400, 213-222.
17. Felix, C. A. (1998) Secondary leukemias induced by topoisomerase-targeted drugs, Biochim. Biophys. Acta 1400, 233-255.
18. Kaufmann, S. H. (1998) Cell death induced by topoisomerase-targeted drugs: more questions than answers, Biochim. Biophys. Acta 1400, 195-211.
19. Pommier, Y., Fesen, M. R., and Goldwasser, F. (1996) Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivatives, in Cancer Chemotherapy and Biotherapy: Principles and Practice (Chabner, B. A., and Longo, D. L., Eds.) pp 435-461, Lippincott-Raven Publishers, Philadelphia.
20. Hande, K. R. (1998) Clinical applications of anticancer drugs targeted to topoisomerase II, Biochim. Biophys. Acta 1400, 173-184.
21. Hande, K. R. (1998) Etoposide: four decades of development of a topoisomerase II inhibitor, Eur. J. Cancer 34, 1514-1521.
22. Rowley, J. D. (1998) The critical role of chromosome translocations in human leukemias, Annu. Rev. Genet. 32, 495-519.
23. Felix, C. A. (2001) Leukemias related to treatment with DNA topoisomerase II inhibitors, Med. Pediatr. Oncol. 36, 525-535.
24. Slater, D. J., Hilgenfeld, E., Rappaport, E. F., Shah, N., Meek, R. G., Williams, W. R., Lovett, B. D., Osheroff, N., Autar, R. S., Ried, T., and Felix, C. A. (2002) MLL-SEPTIN6 fusion recurs in novel translocation of chromosomes 3, X, and 11 in infant acute myelomonocytic leukaemia and in t(X;11) in infant acute myeloid leukaemia, and MLL genomic breakpoint in complex MLL-SEPTIN6 rearrangement is a DNA topoisomerase II cleavage site, Oncogene 21, 4706-4714.
25. Lindsey, R. H., Jr., Bromberg, K. D., Felix, C. A., and Osheroff, N. (2004) 1,4-Benzoquinone is a topoisomerase II poison, Biochemistry 43, 7563-7574.
26. Mistry, A. R., Felix, C. A., Whitmarsh, R. J., Mason, A., Reiter, A., Cassinat, B., Parry, A., Walz, C., Wiemels, J. L., Segal, M. R., Ades, L., Blair, I. A., Osheroff, N., Peniket, A. J., Lafage-Pochitaloff, M., Cross, N. C., Chomienne, C., Solomon, E., Fenaux, P., and Grimwade, D. (2005) DNA topoisomerase II in therapy-related acute promyelocytic leukemia, N. Engl. J. Med. 352, 1529-1538.
27. Pedersen-Bjergaard, J. (2005) Insights into leukemogenesis from therapy-related leukemia, N. Engl. J. Med. 352, 1591-1594.
28. Lavrukhin, O. V., Fortune, J. M., Wood, T. G., Burbank, D. E., Van Etten, J. L., Osheroff, N., and Lloyd, R. S. (2000) Topoisomerase II from chlorella virus PBCV-1. Characterization of the smallest known type II topoisomerase, J. Biol. Chem. 275, 6915-6921.
29. Fortune, J. M., Lavrukhin, O. V., Gurnon, J. R., Van Etten, J. L., Lloyd, R. S., and Osheroff, N. (2001) Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity, J. Biol. Chem. 276, 24401-24408.
30. Fortune, J. M., Dickey, J. S., Lavrukhin, O. V., Van Etten, J. L., Lloyd, R. S., and Osheroff, N. (2002) Site-specific DNA cleavage by chlorella virus topoisomerase II, Biochemistry 41, 11761-11769.
31. Dickey, J. S., Choi, T. J., Van Etten, J. L., and Osheroff, N. (2005) Chlorella virus Marburg topoisomerase II: high DNA cleavage activity as a characteristic of chlorella virus type II enzymes, Biochemistry 44, 3899-3908.
32. Mirski, S. E., Gerlach, J. H., Cummings, H. J., Zirngibl, R., Greer, P. A., and Cole, S. P. (1997) Bipartite nuclear localization signals in the C terminus of human topoisomerase IIα, Exp. Cell Res. 237, 452-455.
33. Jensen, S., Andersen, A. H., Kjeldsen, E., Biersack, H., Olsen, E. H., Andersen, T. B., Westergaard, O., and Jakobsen, B. K. (1996) Analysis of functional domain organization in DNA topoisomerase II from humans and Saccharomyces cerevisiae, Mol. Cell. Biol. 16, 3866-3877.
34. Corbett, K. D., Shultzaberger, R. K., and Berger, J. M. (2004) The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold, Proc. Natl. Acad. Sci. U.S.A. 101, 7293-7298.
35. Qi, Y., Pei, J., and Grishin, N. V. (2002) C-terminal domain of gyrase A is predicted to have a beta-propeller structure, Proteins 47, 258-264.
36. Hsieh, T. J., and Chan, N. L. (2004) Crystallization and preliminary X-ray crystallographic analysis of the C-terminal domain of ParC protein from Bacillus stearothermophilus, Acta Crystallogr., Sect. D: Biol. Crystallogr. 60, 564-566.
37. Hsieh, T. J., Farh, L., Huang, W. M., and Chan, N. L. (2004) Structure of the topoisomerase IV C-terminal domain: a broken beta-propeller implies a role as geometry facilitator in catalysis, J. Biol. Chem. 279, 55587-55593.
38. Shiozaki, K., and Yanagida, M. (1991) A functional 125-kDa core polypeptide of fission yeast DNA topoisomerase II, Mol. Cell. Biol. 11, 6093-6102.
39. Crenshaw, D. G., and Hsieh, T. (1993) Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. I. In vitro studies, J. Biol. Chem. 268, 21328-21334.
40. Crenshaw, D. G., and Hsieh, T. (1993) Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogasler. II. In vivo studies, J. Biol. Chem. 268, 21335-21343.
41. Caron, P. R., Watt, P., and Wang, J. C. (1994) The C-terminal domain of Saccharomyces cerevisiae DNA topoisomerase II, Mol. Cell. Biol., 3197-3207.
42. Englund, P. T. (1978) The replication of kinetoplast DNA networks in Crithidia fasciculata, Cell 14, 157-168.
43. Wasserman, R. A., Austin, C. A., Fisher, L. M., and Wang, J. C. (1993) Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast, Cancer Res. 53, 3591-3596.
44. Kingma, P. S., Greider, C. A., and Osheroff, N. (1997) Spontaneous DNA lesions poison human topoisomerase IIα and stimulate cleavage proximal to leukemic 11q23 chromosomal breakpoints, Biochemistry 36, 5934-5939.
45. Miller, K. G., Liu, L. F., and Englund, P. T. (1981) A homogeneous type II DNA topoisomerase from HeLa cell nuclei, J. Biol. Chem. 256, 9334-9339.
46. Fortune, J. M., and Osheroff, N. (1998) Merbarone inhibits the catalytic activity of human topoisomerase IIα by blocking DNA cleavage, J. Biol. Chem. 273, 17643-17650.
47. Baldwin, E. L., Byl, J. A., and Osheroff, N. (2004) Cobalt enhances DNA cleavage mediated by human topoisomerase II alpha in vitro and in cultured cells. Biochemistry 43, 728-735.
48. O'Reilly, E. K., and Kreuzer, K. N. (2002) A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents, Biochemistry 41, 7989-7997.
49. Robinson, M. J., and Osheroff, N. (1990) Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4′-(9-acridinylamino)methanesulfon-m- anisidide, Biochemistry 29, 2511-2515.
50. Kingma, P. S., Burden, D. A., and Osheroff, N. (1999) Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance, Biochemistry 38, 3457-3461.
51. Osheroff, N. (1989) Effect of antineoplastic agents on the DNA cleavage/religation reaction of eukaryotic topoisomerase II: inhibition of DNA religation by etoposide, Biochemistry 28, 6157-6160.
52. Bromberg, K. D., Velez-Cruz, R., Burgin, A. B., and Osheroff, N. (2004) DNA ligation catalyzed by human topoisomerase II alpha, Biochemistry 43, 13416-13423.
53. Reece, R. J., and Maxwell, A. (1989) Tryptic fragments of the Escherichia coli DNA gyrase A protein, J. Biol. Chem. 264, 19648-19653.
54. Sengupta, T., Mukherjee, M., Mandal, C., Das, A., and Majumder, H. K. (2003) Functional dissection of the C-terminal domain of type II DNA topoisomerase from the kinetoplastid hemoflagellate Leishmania donovani, Nucleic Acids Res. 31, 5305-5316.
55. Niimi, A., Suka, N., Harata, M., Kikuchi, A., and Mizuno, S. (2001) Co-localization of chicken DNA topoisomerase IIalpha, but not beta, with sites of DNA replication and possible involvement of a C-terminal region of alpha through its binding to PCNA, Chromosoma 110, 102-114.